• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

    7/10/24 1:14:41 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KRYS alert in real time by email
    SC 13G/A 1 tv0020-krystalbiotechinc.htm SCHEDULE 13G/A krystalbiotechinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Krystal Biotech Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  501147102

    Date of Event Which Requires Filing of this Statement: June 28, 2024

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  501147102

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    44,379

    7.  SOLE DISPOSITIVE POWER

    2,800,931

    8.  SHARED DISPOSITIVE POWER

    68,205

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,869,136

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.05%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Krystal Biotech Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    2100 Wharton Street, Suite 701
    Pittsburgh, PA 15203

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    501147102

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  July 10, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $KRYS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KRYS

    DatePrice TargetRatingAnalyst
    3/5/2025$245.00Buy
    Jefferies
    8/6/2024$195.00 → $204.00Buy → Neutral
    Citigroup
    11/20/2023$160.00Buy
    Goldman
    10/24/2023$100.00Overweight
    Cantor Fitzgerald
    10/12/2023$160.00Buy
    Citigroup
    9/7/2023$154.00Buy
    Berenberg
    4/18/2023$102.00Buy
    Stifel
    2/28/2023$79.00 → $124.00Neutral → Buy
    Goldman
    More analyst ratings

    $KRYS
    SEC Filings

    View All

    Krystal Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Krystal Biotech, Inc. (0001711279) (Filer)

    8/4/25 7:09:44 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Krystal Biotech Inc.

    10-Q - Krystal Biotech, Inc. (0001711279) (Filer)

    8/4/25 7:04:06 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krystal Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Krystal Biotech, Inc. (0001711279) (Filer)

    7/25/25 9:03:48 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results

    $96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023 VYJUVEK approved in Japan for the treatment of DEB patients from birth Strong balance sheet, ending the quarter with $820.8 million in cash and investments PITTSBURGH, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today reported financial results for the second quarter ending June 30, 2025 and provided a business update. "With the approval of VYJUVEK in Europe and Japan, we are on the cusp of a global expansion that will build on our U.S. sales momentum and dramatically expand VYJUVEK access to DEB patients around the world," said Krish S. Krishnan, Cha

    8/4/25 7:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025

    PITTSBURGH, July 29, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2025 financial results on Monday, August 4, 2025, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, August 4, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster4.com/Webcast/Page/3018/52772. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section o

    7/29/25 7:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

    VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family VYJUVEK is the first and only genetic medicine approved in Japan for the treatment of DEB PITTSBURGH, July 25, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that on July 24, 2025, Japan's Ministry of Health, Labour and Welfare (MHLW) granted marketing authorization to VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB), starting from birth. VYJUVEK is the first genetic medicine approved in Japan

    7/25/25 9:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, R&D Krishnan Suma sold $5,395,001 worth of shares (35,873 units at $150.39), decreasing direct ownership by 1% to 1,438,711 units (SEC Form 4)

    4 - Krystal Biotech, Inc. (0001711279) (Issuer)

    7/16/25 6:42:49 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Krishnan Krish S sold $5,395,001 worth of shares (35,873 units at $150.39), decreasing direct ownership by 1% to 1,508,056 units (SEC Form 4)

    4 - Krystal Biotech, Inc. (0001711279) (Issuer)

    7/16/25 6:41:30 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President, R&D Krishnan Suma sold $2,122,835 worth of shares (14,127 units at $150.27), decreasing direct ownership by 0.48% to 1,456,711 units (SEC Form 4)

    4 - Krystal Biotech, Inc. (0001711279) (Issuer)

    7/11/25 5:45:38 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 19, 2023 - FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

    For Immediate Release: May 19, 2023 Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.  “Vyjuvek is the first FDA-approved gene therapy treatment for DEB, a

    5/19/23 1:48:20 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Krystal Biotech with a new price target

    Jefferies initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $245.00

    3/5/25 7:35:58 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krystal Biotech downgraded by Citigroup with a new price target

    Citigroup downgraded Krystal Biotech from Buy to Neutral and set a new price target of $204.00 from $195.00 previously

    8/6/24 8:53:09 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Goldman initiated coverage on Krystal Biotech with a new price target

    Goldman initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $160.00

    11/20/23 7:47:05 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Financials

    Live finance-specific insights

    View All

    Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results

    $96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023 VYJUVEK approved in Japan for the treatment of DEB patients from birth Strong balance sheet, ending the quarter with $820.8 million in cash and investments PITTSBURGH, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today reported financial results for the second quarter ending June 30, 2025 and provided a business update. "With the approval of VYJUVEK in Europe and Japan, we are on the cusp of a global expansion that will build on our U.S. sales momentum and dramatically expand VYJUVEK access to DEB patients around the world," said Krish S. Krishnan, Cha

    8/4/25 7:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025

    PITTSBURGH, July 29, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2025 financial results on Monday, August 4, 2025, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, August 4, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster4.com/Webcast/Page/3018/52772. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section o

    7/29/25 7:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

    KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally reverse the biology of aging skin, announced today positive safety and efficacy results, including significant improvements in key skin aesthetic attributes such as wrinkles and elasticity, in PEARL-2, a randomized, double-blind, placebo-controlled Phase 1 study evaluating KB30

    7/24/25 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

    SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

    11/14/24 9:00:58 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

    SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

    11/12/24 10:32:12 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Krystal Biotech Inc.

    SC 13G - Krystal Biotech, Inc. (0001711279) (Subject)

    10/16/24 12:28:49 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Leadership Updates

    Live Leadership Updates

    View All

    Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

    PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well as launching and commercializing leading brands, including BOTOX®, one of the most widely recognized global brands. Mr. Forth

    4/7/25 4:30:00 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

    PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he was a Managing Director in Evercore's healthcare group, where he advised on transactions totaling over $500 billion in aggregate value. "It is my

    1/14/25 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

    6/7/24 6:09:00 PM ET
    $ADTN
    $ALTR
    $ATNI
    Telecommunications Equipment
    Utilities
    Computer Software: Prepackaged Software
    Technology